Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 9:04 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 326 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CAP-IT Clear all

Conditions: Low Back Pain
Interventions: MSM 1000mg twice a day (6000 mgs), Placebo capsules twice a day; Drug · Other
Lead sponsor: Mike O'Callaghan Military Hospital; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Nellis Air Force Base, Nevada

Conditions: Brain-derived Neurotrophic Factor (BDNF), Cognitive Function, Affect
Interventions: Whole Coffee Fruit Concentrate (WCFC), Nutrim; Dietary Supplement
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 40 Years to 55 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Inclusion Body Myositis
Interventions: Sirolimus, Placebo; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 45 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Kansas City, Kansas • Baltimore, Maryland

Conditions: Healthy, Body Mass Index, Normal, Postprandial Hyperglycemia
Interventions: Alpha galactosidase, Placebo; Dietary Supplement
Lead sponsor: Iowa State University; Other
Eligibility: 21 Years to 34 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Ames, Iowa

Conditions: Pulmonary Hypertension
Interventions: Bardoxolone methyl; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 261 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 46
States / cities: Phoenix, Arizona • Beverly Hills, California • La Jolla, California + 32 more

Conditions: Psilocybin
Interventions: Psilocybin, Methylphenidate; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 40 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Healthy Adults
Interventions: Crucera-SGS, Meriva 500-SF; Dietary Supplement
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Type 2 Diabetes
Interventions: CRx Health, Chronicare; Other
Lead sponsor: QuiO; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Midland, Michigan

Conditions: Autism Spectrum Disorder
Interventions: Memantine, Placebo; Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 8 Years to 17 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Coronavirus Disease 2019 (COVID-19), Immunocompromised, Hospitalization, Child, Hospitalized
Interventions: Nirmatrelvir, Ritonavir, Placebo for nirmatrelvir; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Cooperstown, New York • New York, New York

Conditions: Marijuana Abuse
Interventions: THC (delta-9 tetrahydrocannabinol), d-amphetamine, oral THC; Drug
Lead sponsor: Wayne State University; Other
Eligibility: 21 Years to 45 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Anterior Cruciate Ligament Reconstruction, Total Hip Arthroplasty (THA), Total Knee Arthroplasty, Hip Arthroscopy
Interventions: Visualization training with neurofeedback, Standard post-surgical rehabilitation therapy; Other
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Smoking, Nicotine Dependence
Interventions: Bupropion; Drug
Lead sponsor: Henry Kranzler; Other
Eligibility: 18 Years and older · Female only
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 3
States / cities: Newark, Delaware • Philadelphia, Pennsylvania

Conditions: HIV-1 Infection
Interventions: ISL, LEN, B/F/TAF, ISL/LEN FDC; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 44
States / cities: Beverly Hills, California • Los Angeles, California • Newport Beach, California + 33 more

Conditions: Cognitive Impairment, Cognitive Decline, Cognition Disorders in Old Age, Well-Being, Psychological, Inflammation, Cognitive Fun
Interventions: LasoperinTM, Placeo; Dietary Supplement
Lead sponsor: Lindenwood University; Other
Eligibility: 30 Years to 60 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Infectious Pneumonia, Severe COVID-19
Interventions: Reparixin, Placebo; Drug · Other
Lead sponsor: Dompé Farmaceutici S.p.A; Industry
Eligibility: 18 Years and older
Enrollment: 414 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 28
States / cities: Tucson, Arizona • Orange, California • Denver, Colorado + 24 more

Conditions: Major Depression
Interventions: D-Cycloserine (DCS), Continuous theta-burst stimulation (cTBS), Transcranial Magnetic Stimulation Sham, Memantine, Lorazepam (drug), Baclofen, Placebo; Drug · Device
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Amyotrophic Lateral Sclerosis
Interventions: AMT-162; Drug
Lead sponsor: UniQure Biopharma B.V.; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 11
States / cities: Phoenix, Arizona • Irvine, California • San Francisco, California + 8 more

Conditions: Neoplasms
Interventions: GSK2636771, Enzalutamide; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 7
States / cities: Duarte, California • Los Angeles, California • Washington D.C., District of Columbia + 3 more

Conditions: Gastroesophageal Reflux Disease (GERD)
Interventions: Dexlansoprazole; Drug
Lead sponsor: Takeda; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 6
States / cities: Mobile, Alabama • San Francisco, California • Atlanta, Georgia + 3 more

Conditions: Nausea, Vomiting
Interventions: Ginger, Placebo Oral Tablet; Drug
Lead sponsor: Joel Yarmush; Other
Eligibility: 20 Years to 49 Years · Female only
Enrollment: 239 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Multiple Myeloma
Interventions: Melflufen, Pomalidomide, Dexamethasone; Drug
Lead sponsor: Oncopeptides AB; Industry
Eligibility: 18 Years and older
Enrollment: 495 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 14
States / cities: Tucson, Arizona • Fresno, California • Gainesville, Florida + 11 more

Conditions: Erosive Esophagitis
Interventions: Dexlansoprazole; Drug
Lead sponsor: Takeda; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 11
States / cities: Mobile, Alabama • San Francisco, California • Miami, Florida + 8 more

Conditions: Erectile Dysfunction
Interventions: Nitric Oxide, Tadalafil, Placebo; Dietary Supplement · Drug · Other
Lead sponsor: RHA Investments Ltd; Industry
Eligibility: 40 Years to 65 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Charlotte, North Carolina

Search by objective public record fields.

The Use of Methylsulfonylmethane (MSM) in the Treatment of Low Back Pain

Whole Coffee Fruit Concentrate Pilot Study 1

Phase III Trial of Sirolimus in IBM

Glycemic Response of Whole Beans and Bean Products

Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER

Precision Functional Brain Mapping in Psilocybin

Effect of Orally Delivered Phytochemicals on Aging and Inflammation in the Skin

Chronicare for Type 2 Diabetes (Chronicare-T2D)

Behavioral and Neural Response to Memantine in Adolescents With Autism Spectrum Disorder

A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19

Marijuana Drug Discrimination and Self-Administration

Brain-Computer Interface Visualization Training to Optimize Muscle Activation Following Orthopaedic Surgery

Placebo-controlled Trial of Bupropion for Smoking Cessation in Pregnant Women

Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV

A Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of LasoperinTM on Cognitive Function in Healthy Adults

Reparixin add-on Therapy to Standard Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia

Synaptic Mechanisms of Continuous Theta Burst Stimulation in Depression

Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)

Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer

A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old

Efficacy of Ginger on Intraoperative and Postoperative Nausea and Vomiting in Elective Cesarean Section Patients

A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide

A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old

The Effects of a Nitrate Supplementation on Erectile Function